Roughly the same number of American men will be diagnosed with prostate cancer (1 in 9) as women will be diagnosed with breast cancer (1 in 8) every year. However, for a variety of reasons, prostate cancer awareness does not employ the same level of awareness breast...
Dr. Brian J. Moran, Medical Director for the Chicago Prostate Cancer Center, stresses the importance of customizing each and every patient’s cancer treatment. “This disease is a spectrum disease,” says Moran. “It’s not one-size-fits-all so we have to identify where...
Dr. Brian J. Moran is the Medical Director for the Chicago Prostate Cancer Center. The Chicago Prostate Cancer Center is a specialty center that practices low-dose rate brachytherapy and has performed over 20,000 low-dose rate prostate implants since they were founded...
Prostate cancer is one of the deadliest and most common cancers among men today. A recent article written by Melissa Matthews published by Newsweek reveals that late detection plays a key role in why prostate cancer is so fatal. Matthews writes in the article:...
Dr. Brian Moran, Medical Director for the Chicago Prostate Center, discusses the value of low-dose rate brachytherapy and its disruptive innovation in the cancer treatment field. Dr. Moran stresses how important it is for clinicians to recognize the value of...
GammaTile Therapy is the Next Step in the Expansion of Cesium to Additional Markets RICHLAND, Wash., July 09, 2018 (GLOBE NEWSWIRE) — IsoRay, Inc. (NYSE American: ISR), a medical technology company and innovator in seed brachytherapy and medical radioisotope...
With the 2018 edition of the American Brachytherapy Annual Meeting in the books, it is fitting to take a few minutes and highlight our top ABS 2018 Insights. The clinical experience with Cesium-131 continues to build: Dr. Manuj Agarwal of the University of Maryland...
“Prostate cancer patients treated with Cesium-131 brachytherapy maintained their urinary- and bowel-related quality of life years afterward, according to a recent study.” The study, “Long-term Quality of Life in Prostate Cancer Patients Treated with Cesium-131,” was...
More news in the ‘brachytherapy beyond prostate cancer’ realm: “U.S. News & World Report: Cesium-131 featured in US News & World Report “10 Innovations in Cancer Therapy” We remain excited by the mounting evidence that certain types of recurrent cancerous...
We remain excited by the mounting evidence that certain types of recurrent cancerous brain tumors can be effectively treated with Cesium-131 brachytherapy, prolonging survival and improving quality of life at the same time. From Lisa Esposito and Kristine Crane in...
